stage 4S neuroblastoma
Showing 1 - 25 of >10,000
Neuroblastoma, Ganglioneuroblastoma Trial in Moscow (monoclonal antibodies GD2)
Recruiting
- Neuroblastoma
- Ganglioneuroblastoma
- monoclonal antibodies GD2
-
Moscow, Russian FederationResearch Institute of Pediatric Hematology, Oncology and Immunol
Oct 4, 2023
Disseminated Neuroblastoma, Ganglioneuroblastoma, Localized Resectable Neuroblastoma Trial in United States (drug, radiation,
Active, not recruiting
- Disseminated Neuroblastoma
- +5 more
- cyclophosphamide
- +18 more
-
Birmingham, Alabama
- +22 more
Mar 3, 2022
Patients With Previously Diagnosed High-Risk Neuroblastoma
Active, not recruiting
- Recurrent Neuroblastoma
- +5 more
- Cytology Specimen Collection Procedure
- +2 more
-
Birmingham, Alabama
- +97 more
Oct 28, 2022
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma Trial in Australia, Canada,
Completed
- Localized Resectable Neuroblastoma
- +4 more
- Clinical Observation
- +5 more
-
Birmingham, Alabama
- +103 more
Jan 4, 2023
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in
Active, not recruiting
- Metastatic Melanoma
- +22 more
- Ipilimumab
- +3 more
-
Birmingham, Alabama
- +24 more
Jan 19, 2023
Neuroblastoma Trial in Guangzhou (Anti Thymocyte Globulin, Fludarabine, Cyclophosphamide injection)
Not yet recruiting
- Neuroblastoma
- Anti Thymocyte Globulin
- +10 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Jun 29, 2022
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma Trial in Worldwide
Active, not recruiting
- Localized Resectable Neuroblastoma
- +5 more
- Aldesleukin
- +6 more
-
Birmingham, Alabama
- +196 more
Dec 30, 2022
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma Trial in Worldwide (drug,
Active, not recruiting
- Disseminated Neuroblastoma
- +4 more
- cyclophosphamide
- +14 more
-
Birmingham, Alabama
- +120 more
Mar 3, 2022
Neuroblastoma Trial in Guangzhou (Arsenic Trioxide)
Recruiting
- Neuroblastoma
- Arsenic Trioxide
-
Guangzhou, Guangdong, ChinaSun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 29, 2021
Ch14.18 in Younger Patients With High-Risk Neuroblastoma
Completed
- Localized Resectable Neuroblastoma
- +6 more
- Cytology Specimen Collection Procedure
- Pharmacological Study
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Sep 30, 2019
Diabetes Type 2 With Proteinuria, Diabetes, Type 2, Diabetes Trial (drug, device, diagnostic test, behavioral)
Not yet recruiting
- Diabetes Mellitus Type 2 With Proteinuria
- +12 more
- Empagliflozin 10 MG
- +6 more
- (no location specified)
Oct 17, 2023
Tumor Tissue Samples From Newly Diagnosed Neuroblastoma or
Recruiting
- Ganglioneuroblastoma
- +5 more
- Cytology Specimen Collection Procedure
- Laboratory Biomarker Analysis
-
Birmingham, Alabama
- +258 more
Mar 23, 2022
Ganglioneuroblastoma, High Risk Neuroblastoma Trial in Australia, New Zealand, United States (procedure, drug, biological,
Active, not recruiting
- Ganglioneuroblastoma
- High Risk Neuroblastoma
- Autologous Hematopoietic Stem Cell Transplantation
- +14 more
-
Los Angeles, California
- +9 more
Sep 1, 2022
Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell
Active, not recruiting
- Stage I Lung Non-Small Cell Cancer AJCC v7
- +6 more
- Carboplatin
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Oct 24, 2022
Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in
Recruiting
- Advanced Malignant Solid Neoplasm
- +32 more
- Laboratory Biomarker Analysis
- +2 more
-
Birmingham, Alabama
- +124 more
Aug 24, 2022
Immunotherapy, Second-line Treatment Trial in Guizhou (Cadonilimab)
Recruiting
- Immunotherapy
- Second-line Treatment
-
Guizhou, ZunYi, ChinaThe Second Affiliated Hospital of Zunyi Medical University
Jun 14, 2023
Advanced Malignant Solid Tumor, Bile Duct Carcinoma, Recurrent Malignant Solid Tumor Trial in Indianapolis, Seattle (Afatinib
Completed
- Advanced Malignant Solid Neoplasm
- +6 more
- Afatinib Dimaleate
- +2 more
-
Indianapolis, Indiana
- +1 more
Jun 3, 2022
ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma Trial
Recruiting
- ENSAT Stage I Adrenal Cortex Carcinoma
- +2 more
- Cisplatin
- +3 more
-
Ann Arbor, Michigan
- +3 more
Dec 13, 2022
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma Trial
Not yet recruiting
- Advanced Esophageal Adenocarcinoma
- +14 more
- Fluorouracil
- +8 more
- (no location specified)
Jan 3, 2023
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical
Not yet recruiting
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8
- +5 more
- Biospecimen Collection
- +9 more
-
Scottsdale, Arizona
- +2 more
Oct 11, 2023
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma Trial in Worldwide (Carboplatin,
Recruiting
- Ganglioneuroblastoma
- +3 more
- Carboplatin
- +6 more
-
Birmingham, Alabama
- +219 more
Aug 17, 2022
Lung Cancer, Non Small Cell Lung Cancer, NSCLC Stage I Trial in Canada (Selective Targeted Sampling, Systematic Sampling)
Completed
- Lung Cancer
- +3 more
- Selective Targeted Sampling
- Systematic Sampling
-
Edmonton, Alberta, Canada
- +6 more
Jul 25, 2022
Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma Trial in United States
Recruiting
- Advanced Colorectal Carcinoma
- +26 more
- Irinotecan
- +2 more
-
Tampa, Florida
- +3 more
Jun 22, 2022
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial in
Suspended
- Anatomic Stage 0 Breast Cancer AJCC v8
- +18 more
- Celecoxib
- +6 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 4, 2022